Chemours Faces Investor Securities-Fraud Class Action
Investors who bought Chemours securities from Feb. 20 through Aug. 4, 2026, are covered by a securities class action alleging the company overstated demand for its Opteon refrigerants and issued unreliable 2026 financial guidance amid excess distributor inventory. Chemours cut its full-year adjusted EBITDA outlook on Aug. 4, and its shares fell 18.63% the next day. The case is pending in federal court in Delaware, where investors seeking to serve as lead plaintiff must apply by Dec. 7, 2026; the allegations have not been proven.







